Lofexidine

Lofexidine

Clinical data
Trade names	Britlofex
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	N07BC04 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	>90%
Protein binding	80–90%
Metabolism	Hepatic glucuronidation
Elimination half-life	11 hours
Excretion	Renal
Identifiers
IUPAC name (RS)-2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole
CAS Number	31036-80-3 Y
PubChem CID	30668
DrugBank	DB04948 N
ChemSpider	28460 Y
UNII	UI82K0T627
KEGG	D08141 Y
ChEBI	CHEBI:51368 N
ChEMBL	ChEMBL17860 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C11H12Cl2N2O
Molar mass	259.131 g/mol
3D model (JSmol)	Interactive image
SMILES Clc2c(OC(C/1=N/CCN\1)C)c(Cl)ccc2
InChI InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15) Y Key:KSMAGQUYOIHWFS-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Lofexidine
Articles
Most recent articles on Lofexidine Most cited articles on Lofexidine Review articles on Lofexidine Articles on Lofexidine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lofexidine Images of Lofexidine Photos of Lofexidine Podcasts & MP3s on Lofexidine Videos on Lofexidine
Evidence Based Medicine
Cochrane Collaboration on Lofexidine Bandolier on Lofexidine TRIP on Lofexidine
Clinical Trials
Ongoing Trials on Lofexidine at Clinical Trials.gov Trial results on Lofexidine Clinical Trials on Lofexidine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lofexidine NICE Guidance on Lofexidine NHS PRODIGY Guidance FDA on Lofexidine CDC on Lofexidine
Books
Books on Lofexidine
News
Lofexidine in the news Be alerted to news on Lofexidine News trends on Lofexidine
Commentary
Blogs on Lofexidine
Definitions
Definitions of Lofexidine
Patient Resources / Community
Patient resources on Lofexidine Discussion groups on Lofexidine Patient Handouts on Lofexidine Directions to Hospitals Treating Lofexidine Risk calculators and risk factors for Lofexidine
Healthcare Provider Resources
Symptoms of Lofexidine Causes & Risk Factors for Lofexidine Diagnostic studies for Lofexidine Treatment of Lofexidine
Continuing Medical Education (CME)
CME Programs on Lofexidine
International
Lofexidine en Espanol Lofexidine en Francais
Business
Lofexidine in the Marketplace Patents on Lofexidine
Experimental / Informatics
List of terms related to Lofexidine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Lofexidine (sold under the brand names: Britlofex and Kai Er Ding) is an α_2A-adrenergic receptor agonist, historically used as an anti-hypertensive, but more commonly used to alleviate the physical symptoms of heroin and other types of opioid withdrawal.

Indication

In the United Kingdom, the hydrochloride form, lofexidine HCl, has been licensed and sold since 1992 for opiate withdrawal relief in tablet form as Britlofex by Britannia Pharmaceuticals. Britlofex is only available by prescription. Lofexidine is also commonly used in conjunction with the opioid receptor antagonist naltrexone in rapid detoxification cases. When these two drugs are paired, naltrexone is administered to induce an opioid-receptor blockade sending the subject into immediate withdrawal and accelerating the detoxification process, while lofexidine is given to relieve the symptoms associated with the withdrawal including chills, sweating, stomach cramps, muscle pain, and runny nose.

Lofexidine inhibits the release of norepinephrine in the central and peripheral nervous system, thereby reducing some of the withdrawal symptoms, but it has no documented effect on drug craving and endogenous opioid levels.

Use in opioid detoxification

Lofexidine is not an opioid, whereas methadone is. Some opioid detox programs use methadone in decreasing amounts in their detox protocol, whereas other detox programs use lofexidine. The drugs are completely chemically unrelated, and their physiological effects are completely unrelated, although both are used as part of an opioid detoxification protocol. Whereas lofexidine cannot stop opioid withdrawal and merely eases some symptoms of withdrawal, methadone—being an opioid itself—will completely ameliorate all withdrawal symptoms in a sufficient dose. Indeed, one suggested use for lofexidine is to ease withdrawal symptoms of methadone dependence. While abstaining from opiates and taking lofexidine, effective detoxification can succeed in as little as 3 days , although the standard duration of detoxification using lofexidine is 10 days. The Template:LD50 of lofexidine is 77 mg/kg. Lofexidine is not currently available in the United States. Britannia Pharmaceuticals has licensed lofexidine to be sold by US World Meds for sale in North America, and clinical trials are currently underway to secure approval for sale in the United States by the U.S. Food and Drug Administration (FDA).

An additional benefit of lofexidine treatment is that it is given as part of an outpatient, or ambulatory regimen, and can be completed without a hospital stay. This reduces costs for both healthcare provider and patient, and keeps specialist hospital beds free for particularly difficult withdrawal cases.

Structural similarities to clonidine

Structure of Lofexidine and Clonidine

Lofexidine is structurally analogous to clonidine, another alpha2-adrenergic receptor agonist used for treatment of opioid withdrawal symptoms. A comparison of the two structures is shown at right. Both contain an imidazole ring and a 2,6-dichlorinated phenyl ring. The differences in structure are shown in red, while the similarities are in black. In addition to the structural differences, administration of lofexidine in heroin addicts has been shown to be more effective for a longer duration, with fewer withdrawal symptoms than clonidine even after one day. However, Clonidine is often preferred as it is substantially cheaper than Lofexidine when purchased with a private (non-NHS) prescription. This factor is exacerbated by the considerable number of and quantities of medications prescribed to alleviate the constellation of withdrawal signs and symptoms. Additionally, clonidine has been shown to significantly lower blood pressure. Therefore, although similar to lofexidine, clonidine is most frequently prescribed to treat high-blood pressure.

Other clinical uses

The possibility of using lofexidine to treat alcohol addiction withdrawal symptoms has been investigated, and has not yet been shown to be an effective treatment.

Adverse side effects

• Drowsiness
• Dry mouth
• Dry Nose
• Hypotension
• Dizziness

See also

• Methadone
• Naltrexone
• Clonidine

External links

• BritLofex Official Website